Home › Companies › TVTX

Travere Therapeutics, Inc.

TVTX Rare disease Lead: Approved 7 Biotech Distilled articles ↓

Metabolic Renal Protein Small Molecule

Most recent annual filing: 2026-02-15

Pipeline (4 active programs)

FILSPARI

sparsentan

Small Molecule Target: endothelin type A receptor, angiotensin II type 1 receptor, endothelin-1, angiotensin II

IgA Nephropathy Approved oral CSL Vifor
Focal Segmental Glomerulosclerosis Approved oral CSL Vifor

pegtibatinase

Protein Target: cystathionine beta-synthase

Homocystinuria Phase 3

Thiola

Thiola EC · tiopronin

Cystinuria Approved oral Mission Pharmacal

Biotech Distilled coverage (7)

2026-05-08 UPDATE: Travere Therapeutics (TVTX) - The Convert Math Prints, And It’s Better Than I Modeled 🔒 Paid
2026-05-06 UPDATE: Travere Therapeutics (TVTX) - The $400M Convert Refi Lands One Day After the Q1 Print 🔒 Paid
2026-05-04 UPDATE: Travere Therapeutics (TVTX) - The Profitability Inflection Arrives
2026-04-18 UPDATE: Travere Therapeutics (TVTX) - The FDA Folds, The Bulls Win, and FILSPARI Gets the FSGS Crown 🔒 Paid
2026-04-04 UPDATE: Travere Therapeutics (TVTX) - The C-Suite is Selling 12 Days Before the FDA Verdict 🔒 Paid
2026-02-21 UPDATE: Travere Therapeutics (TVTX) - Commercial Liftoff, CMC Recovery, and Why the Smart Money is Trimming 🔒 Paid
2026-02-06 Travere Therapeutics (TVTX): Scientific Deep Dive for Sparsentan, Pegtibatinase, and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.